Phase 1/2 × Gastrointestinal Neoplasms × Genitourinary × Clear all
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts